BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
Funds will fuel sales team expansion and broader market access, advancing the company’s leadership in Implantable Tibial Neuromodulation (ITNM) for the treatment of urgency urinary incontinence (UUI)
BlueWind Medical’s Revi™ System Secures U.S. FDA De Novo Classification Grant for the Treatment of Urgency Incontinence
Revi redefines the treatment of Urgency Incontinence with a patient-centric implantable tibial neuromodulation solution that empowers patients
BlueWind Medical Raises $64 Million to Fund Innovative Technology for Overactive Bladder (OAB) Treatment
RENOVA iStim™ implantable tibial neuromodulation device is being studied as a minimally invasive, patient-centric solution for the treatment of OAB.
Bluewind Medical™ Ltd. Completes OASIS Study Patient Enrollment
Bluewind Medical announced the successful completion of patient enrollment in the OASIS pivotal clinical study that will be the basis by which the company will seek US-FDA (Food & Drug Administration) marketing clearance in the United States. OASIS is a 150-patient prospective clinical study designed to demonstrate the safety and efficacy of Bluewind Medical’s RENOVA […]
BlueWind Medical enrolls 100th patient in OASIS study of Renova iStim system
BlueWind Medical has announced that the 100th patient has been enrolled in its OASIS (Overactive bladder stimulation system) study—a clinical pivotal trial designed to test the safety and efficacy of the Renova iStim system in providing tibial neuromodulation (TNM) therapy.
